{"groups":[{"description":"Placebo administered orally (PO) once daily (QD)through Week 24.\n\nParticipants continued to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.","id":"FG000","title":"Placebo"},{"description":"Baricitinib 2 mg PO QD through Week 24.\n\nParticipants continued to take background cDMARD therapy throughout study.","id":"FG001","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg PO QD through Week 24.\n\nParticipants continued to take background cDMARD therapy throughout study.","id":"FG002","title":"Baricitinib 4 mg"},{"description":"Baricitinib 4 mg administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"FG003","title":"Rescue"},{"description":"No study drug received. Participants return for safety follow-up visit 28 days after the last dose of study drug.","id":"FG004","title":"Placebo-Follow Up"},{"description":"No study drug received. Participants return for safety follow-up visit 28 days after the last dose of study drug.","id":"FG005","title":"Baricitinib 2 mg- Follow Up"},{"description":"No study drug received. Participants return for safety follow-up visit 28 days after the last dose of study drug.\n\nIncludes participants who were rescued to Baricitinib 4 mg.","id":"FG006","title":"Baricitinib 4 mg- Follow Up"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"5"},{"groupId":"FG002","numSubjects":"8"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"10"},{"groupId":"FG002","numSubjects":"12"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"Lack of Efficacy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"228"},{"groupId":"FG001","numSubjects":"229"},{"groupId":"FG002","numSubjects":"227"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"228"},{"groupId":"FG001","numSubjects":"229"},{"groupId":"FG002","numSubjects":"227"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"Received at Least 1 Dose of Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"55"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"15"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"Rescued"},{"achievements":[{"comment":"\"Completers\" include rescued participants.","groupId":"FG000","numSubjects":"200"},{"comment":"\"Completers\" include rescued participants.","groupId":"FG001","numSubjects":"210"},{"comment":"\"Completers\" include rescued participants.","groupId":"FG002","numSubjects":"204"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"28"},{"groupId":"FG001","numSubjects":"19"},{"groupId":"FG002","numSubjects":"23"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Treatment Period"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"2"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"Lack of Efficacy"}],"milestones":[{"achievements":[{"comment":"Participants who were nonresponders based on tender/swollen joint count entered into rescue group.","groupId":"FG000","numSubjects":"0"},{"comment":"Participants who were nonresponders based on tender/swollen joint count entered into rescue group.","groupId":"FG001","numSubjects":"0"},{"comment":"Participants who were nonresponders based on tender/swollen joint count entered into rescue group.","groupId":"FG002","numSubjects":"0"},{"comment":"Participants who were determined to be nonresponders based on tender/swollen joint count.","groupId":"FG003","numSubjects":"91"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"88"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Rescue Period"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"comment":"Rescued participants who entered post-treatment follow-up are included in Baricitinib 4 mg FollowUp","groupId":"FG003","numSubjects":"0"},{"comment":"Participants from treatment who entered the post-treatment follow-up period.","groupId":"FG004","numSubjects":"17"},{"comment":"Participants from treatment who entered the post-treatment follow-up period.","groupId":"FG005","numSubjects":"19"},{"comment":"Participants from treatment and rescue who entered the post-treatment follow-up period.","groupId":"FG006","numSubjects":"22"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"17"},{"groupId":"FG005","numSubjects":"19"},{"groupId":"FG006","numSubjects":"22"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Follow Up"}],"preAssignmentDetails":"Participants who did not respond (nonresponders) to study drug were eligible for rescue treatment beginning at Week 16.\n\nNonresponders were defined as lack of improvement of at least 20% in both tender joint count and swollen joint count at both Weeks 14 and 16 compared to baseline."}